Results 11 to 20 of about 387,352 (250)

Off-label dermatologic uses of IL-23 inhibitors

Journal of Dermatological Treatment
Background While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels ...
Justin Porter, Lacey Zimmerman, Melissa Nickles, Sheryl Hoyer   +3 more
doaj   +3 more sources

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits [PDF]

Dermatology Practical & Conceptual
Introduction: Psoriasis is a chronic inflammatory multisystem disease for which IL-17 and IL-23 inhibitors have transformed treatment. However, high costs, and the possibility of overtreatment in patients with excellent and sustained responses have ...
Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo, Andrealuna Ucciero, Luca Mastorino, Veronica Arese, Lorenza Burzi, Franco Castelli, Massimo Chiarpenello, Francesca Graziola, Claudia Leporati, Michela Ortoncelli, Pella Paolo, Ginevra Pertusi, Alessia Pisterna, Pietro Quaglino, Simone Ribero, Gianluca Rossotto, Rossana Tiberio, Paolo Dapavo, Paola Savoia   +20 more
doaj   +2 more sources

Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials [PDF]

Frontiers in Medicine
BackgroundInterleukin-23 (IL-23) plays a central role in the pathogenesis of ulcerative colitis (UC) by promoting Th17-mediated intestinal inflammation. While monoclonal antibodies targeting the IL-23p19 subunit have shown promise in clinical trials, the
Minyang He, Huixian Liang, Xiangcheng Fan, Xiangcheng Fan, Leimin Sun, Leimin Sun   +5 more
doaj   +2 more sources

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials [PDF]

Central European Journal of Immunology, 2023
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou   +9 more
doaj   +2 more sources

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies—A Scoping Review [PDF]

Life
Psoriatic arthritis (PsA) is a systemic autoimmune inflammatory disease affecting both the joints and the skin, with the potential involvement of multiple organ systems.
Lambros Athanassiou, Ifigenia Kostoglou-Athanassiou, Georgia Kaiafa, Christos Savopoulos, Yehuda Shoenfeld, Panagiotis Athanassiou   +5 more
doaj   +2 more sources

MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review [PDF]

Therapeutic Advances in Gastroenterology
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals.
José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez   +3 more
doaj   +2 more sources

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) [PDF]

Dermatology and Therapy
Introduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D’Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Anna Campanati, Matteo Megna, Tommaso Bianchelli, for the Italian Landscape Group, Antonio Costanzo, Simone Ribero, Alessandra Narcisi   +33 more
doaj   +2 more sources

Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective

Dermatology and Therapy, 2023
Psoriasis vulgaris is a systemic, chronic inflammatory disease affecting 2–3% of the population. Recent advances in the understanding of the pathophysiology of psoriatic disease have facilitated the development of novel therapeutic options with improved ...
Riley K. Spencer, Kareem G. Elhage, Joy Q. Jin, Mitchell S. Davis, Marwa Hakimi, Tina Bhutani, Howard Chang, Wilson Liao   +7 more
doaj   +1 more source

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

The Lancet Regional Health. Europe, 2022
Summary: Background: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis ...
Linda Davidson, Juul M.P.A. van den Reek, Mariolina Bruno, Florence van Hunsel, Ron M.C. Herings, Vasiliki Matzaraki, Collins K. Boahen, Vinod Kumar, Hans M.M. Groenewoud, Frank L. van de Veerdonk, Mihai G. Netea, Elke M.G.J. de Jong, Bart Jan Kullberg   +12 more
doaj   +1 more source

Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

Clinical Kidney Journal, 2023
ABSTRACT We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after ...
Stryckers, Marijke, Van Oevelen, Stefaan, Koshy, Priyanka, Sprangers, Ben, Van Craenenbroeck, Amaryllis H.   +4 more
openaire   +4 more sources